

LIST OF UPDATES ON DRGD FIRST EDITION JANUARY 2013, REVISED JULY 2015

NO.	REVISION	UPDATES		REFERENCE
		SECTION/ APPENDIX	DETAILS	
1.	July 2015	Section A : General Overview.	<p>Amendment at Subsection 5.1.4 : Registration of Orphan Product</p> <p>2. For all categories of products namely new chemical entities/new drugs, biologics and generics (including Non-Scheduled Poison product):</p> <p>i. Application for registration that being submitted to National Pharmaceutical Control Bureau (NPCB) will only be accepted/ considered after the products have been designated as orphan products. by the Pharmacy Practice and Development Division, Pharmaceutical Services Division, Ministry of Health, Malaysia.</p>	-
2.	July 2015	Appendix 5 : Guidelines on Registration of Natural Products	<p>Amendment at Subappendix 2.7 : LABELLING REQUIREMENT;</p> <p>Subappendix 2.7.3 : CAUTIONARY STATEMENT FOR PRODUCTS SPECIALLY USED IN WOMEN</p> <p>However, for products containing any ingredients as listed in the following lists, i.e. List of Prohibited Ingredients in Pregnancy and List</p>	-

NO.	REVISION	UPDATES		REFERENCE
		SECTION/ APPENDIX	DETAILS	
			<p>of Restricted Ingredients in Pregnancy, the following cautionary statement shall be stated in the product label:</p> <p>i) Prohibited Ingredients in Pregnancy: “Contraindicated in pregnant women. Insufficient reliable data in breastfeeding women”</p> <p>ii) Restricted Ingredients in Pregnancy: “To be used with caution in pregnancy. Insufficient reliable data in breastfeeding women”</p>	
3.	July 2015	Section E : Post registration Process	<p>Amendment at Subsection 14 : MAINTENANCE OF REGISTRATION</p> <p>Addition of the following Subsections;</p> <p>a) Subsection 14.1 : Re-registration Application</p> <p>b) Subsection 14.2 : Re-registration Processing Fee</p>	-

NO.	REVISION	UPDATES		REFERENCE						
		SECTION/ APPENDIX	DETAILS							
4.	July 2015	APPENDIX 9 : Labelling Requireme nt	<p>Amendment at Subappendix 9.2 : SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC)</p> <p>Addition of information on specific labelling requirements for products containing DOMPERIDONE and link to related circular.</p> <table border="1"> <thead> <tr> <th>NO.</th> <th>SUBSTANCES</th> <th>ADDITION OF INFORMATION</th> </tr> </thead> <tbody> <tr> <td>112.</td> <td>DOMPERIDONE</td> <td> i) WARNINGS ii) THERAPEUTIC INDICATIONS iii) DOSAGE AND ADMINISTRATION iv) CONTRAINDICATIONS v) WARNINGS AND PRECAUTIONS vi) ADVERSE REACTIONS </td> </tr> </tbody> </table>	NO.	SUBSTANCES	ADDITION OF INFORMATION	112.	DOMPERIDONE	i) WARNINGS ii) THERAPEUTIC INDICATIONS iii) DOSAGE AND ADMINISTRATION iv) CONTRAINDICATIONS v) WARNINGS AND PRECAUTIONS vi) ADVERSE REACTIONS	<p>Reference Directive : (28)dIm.bpfk/ppp/07/25 ;</p> <p>Arahan Pengarah Kanan Perkhidmatan Farmasi Bilangan 4 Tahun 2015 : Direktif Untuk Semua Produk Domperidone Untuk Menghadkan Penggunaan Berikutan Risiko Kesan Advers Jantung</p>
NO.	SUBSTANCES	ADDITION OF INFORMATION								
112.	DOMPERIDONE	i) WARNINGS ii) THERAPEUTIC INDICATIONS iii) DOSAGE AND ADMINISTRATION iv) CONTRAINDICATIONS v) WARNINGS AND PRECAUTIONS vi) ADVERSE REACTIONS								

NO.	REVISION	UPDATES		REFERENCE									
		SECTION/ APPENDIX	DETAILS										
5.	July 2015	APPENDIX 9 : Labelling Requireme nt	<p>Amendment at Subappendix 9.2 : SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC)</p> <p>Addition of information on specific labelling requirements for products containing PARACETAMOL (including combination product) and link to related circular.</p> <table border="1"> <thead> <tr> <th>NO.</th> <th>SUBSTANCES</th> <th>ADDITION OF INFORMATION</th> </tr> </thead> <tbody> <tr> <td>112.</td> <td>PARACETAMOL</td> <td> i) WARNINGS ii) ADVERSE EFFECT/UNDESIRABLE EFFECT </td> </tr> <tr> <td>113.</td> <td>PARACETAMOL WITH CAFFEINE IN COMBINATION</td> <td> i) WARNINGS ii) ADVERSE EFFECT/UNDESIRABLE EFFECT </td> </tr> </tbody> </table>	NO.	SUBSTANCES	ADDITION OF INFORMATION	112.	PARACETAMOL	i) WARNINGS ii) ADVERSE EFFECT/UNDESIRABLE EFFECT	113.	PARACETAMOL WITH CAFFEINE IN COMBINATION	i) WARNINGS ii) ADVERSE EFFECT/UNDESIRABLE EFFECT	<p>Reference Directive : (29)dlm.bpfk/ppp/07/25 ;</p> <p>Arahan Pengarah Kanan Perkhidmatan Farmasi Bilangan 5 Tahun 2015 : Direktif Untuk Produk Yang Mengandungi Paracetamol, Termasuk Produk Kombinasi : Pengemaskinian Label, Sisip Bungkus, Dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) Dengan Amaran Berkaitan Kesan Advers Serious Pada Kulit</p>
NO.	SUBSTANCES	ADDITION OF INFORMATION											
112.	PARACETAMOL	i) WARNINGS ii) ADVERSE EFFECT/UNDESIRABLE EFFECT											
113.	PARACETAMOL WITH CAFFEINE IN COMBINATION	i) WARNINGS ii) ADVERSE EFFECT/UNDESIRABLE EFFECT											

NO.	REVISION	UPDATES		REFERENCE
		SECTION/ APPENDIX	DETAILS	
6.	July 2015	SECTION A : General Overview.	<p>Amendment at Subsection 5.2.5 APPLICATION FOR A CONVENIENT PACK</p> <p>5.2.5 APPLICATION FOR A CONVENIENT PACK</p> <p>a) Refers to products which are packed together in a single packaging unit for convenience of the consumers, such as a Confinement Set or <i>Set Jamu Bersalin</i>.</p> <p>b) Shall consist of registered products only.</p> <p>c) Applicable to health supplements and natural products only.</p> <p>The convenient pack is applicable for registered products in the categories of;</p> <p>i) Health supplements.</p> <p>ii) Natural products.</p> <p>Or registered products from both categories (i) and (ii)</p> <p>iii) Non-Scheduled Poison (OTC)</p> <p>(Only between OTC products with Abridge Evaluation category)</p> <p>d) Application for a convenient pack shall be made via the variation process.</p>	-

NO.	REVISION	UPDATES		REFERENCE							
		SECTION/ APPENDIX	DETAILS								
7.	July 2015	SECTION B : Product Registration Process	<p>Amendment at Subsection 8.1.2 METHOD OF EVALUATION; Table VI : Products containing Glucosamine, Chondroitin and Methylsulphonylmethane (MSM)</p> <p>Amendment of information on remarks for products containing Glucosamine and link to related circular.</p> <table border="1"> <thead> <tr> <th>No.</th> <th>Product</th> <th>Remark</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>Products containing Glucosamine</td> <td> <p>As single active ingredient</p> <p>As combination with Chondroitin and/ or MSM</p> </td> <td> <p>As combination with other supplement ingredients are NOT allowed to be registered</p> <p>Products containing glucosamine in combination with other health supplement ingredients are only allowed to be registered for therapeutic purposes and NOT allowed to be registered as Health Supplement Product.</p> </td> </tr> </tbody> </table>	No.	Product	Remark	1.	Products containing Glucosamine	<p>As single active ingredient</p> <p>As combination with Chondroitin and/ or MSM</p>	<p>As combination with other supplement ingredients are NOT allowed to be registered</p> <p>Products containing glucosamine in combination with other health supplement ingredients are only allowed to be registered for therapeutic purposes and NOT allowed to be registered as Health Supplement Product.</p>	<p><i>Reference Circular : Bil. (20) dlm.BPFK/PPP/01/ 03 : Produk yang mengandung Glucosamine, Chondroitin dan Methylsulfonylmet hane (MSM)</i></p>
No.	Product	Remark									
1.	Products containing Glucosamine	<p>As single active ingredient</p> <p>As combination with Chondroitin and/ or MSM</p>	<p>As combination with other supplement ingredients are NOT allowed to be registered</p> <p>Products containing glucosamine in combination with other health supplement ingredients are only allowed to be registered for therapeutic purposes and NOT allowed to be registered as Health Supplement Product.</p>								

NO.	REVISION	UPDATES		REFERENCE
		SECTION/ APPENDIX	DETAILS	
8.	July 2015	APPENDIX 9 : Labelling Requireme nt	<p>Addition of Subappendix 9.1.4 : PRODUCT NAME</p> <p>Addition of information and reference table on guidance for constructing product names and list of non-permissible words/ sentences for product names.</p>	-
9.	July 2015	APPENDIX 9 : Labelling Requireme nt	<p>Addition of Subappendix 9.1.5 : PROHIBITED VISUAL/ GRAPHIC/ STATEMENT</p> <p>Addition of information and reference table on prohibited visual/ graphic/ statements that are not permitted to be used on product labels.</p>	-